Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

University of California, Los Angeles · NCT05419726

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
20
US sites recruiting
1
Study start
February 1, 2023
Record last updated
May 11, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role.

We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.

Being studied: Semaglutide Injectable Product (not provided by the study)

Conditions: Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
  • >18 years of age and willing to participate
  • Male or post-menopausal females

Exclusion Criteria

  • History of prior neck surgery and /or neck irradiation
  • Use of beta blocker agents
  • Use of any other glucose lowering medication
  • History of neuropathic disorders (e.g. diabetic neuropathy)
  • Diabetic patients
  • Individuals without normal thyroid function
  • Individuals with cancer
  • Any significant chronic disease or renal, hepatic or endocrine disease
  • Current smokers
  • Inability of patient to provide consent either for medical reasons or psychiatric reasons

Recruiting US locations

  • UCLA Health

    Los Angeles, CA 90095

    Site contact: Julie Sorg, MSN · jsorg@mednet.ucla.edu

Study contacts (from the official record)

  • Preethi Srikanthan, MD · 310-825-7922 · psrikanthan@mednet.ucla.edu
  • Julie Sorg, MSN · 310-206-2235 · jsorg@mednet.ucla.edu
All weight loss studies in California →
Brown Adipose Tissue Activity in Response to Semaglutide… (NCT05419726) | Bored Studies